EGFR and breast cancer: In the continued search for additional biomarkers that may be predictive of response to anti-EGFR agents, we and others [12] have extrapolated data from breast cancer [54], colorectal cancer [22, 26], and NSCLC [20] in order to address additional candidate genes/biomarkers to receptor tyrosine kinases in general.